Clinical Trials Browser

Phase 2/3 × Breast Diseases × Capecitabine × Clear all

NCT03500380 2024-02-20

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Phase 2/3 Unknown

Breast Diseases, Breast Neoplasms